Traws Pharma, Inc. Research And Development Expense

Quick Answer

Traws Pharma, Inc. reported Research And Development Expense of $11.43 million for the year ending 2023.

  • Traws Pharma, Inc. showed an increase of +0.2% in Research And Development Expense from 2022 to 2023.
  • This data is from Traws Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2024.
  • XBRL data for this metric is available from 2011 to 2023 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2012: $8.45 million | Q2 2012: $6.78 million | Q3 2012: $26.96 million | Q4 2012: $10.58 million | Q1 2013: $12.76 million | Q2 2013: $10.05 million | Q3 2013: $15.29 million | Q4 2013: $12.09 million | Q1 2014: $14.25 million | Q2 2014: $12.90 million | Q3 2014: $11.89 million | Q4 2014: $10.39 million | Q1 2015: $9.50 million | Q2 2015: $6.51 million | Q3 2015: $5.28 million | Q1 2016: $5.82 million | Q2 2016: $5.56 million | Q3 2016: $3.99 million | Q1 2017: $4.89 million | Q2 2017: $4.61 million | Q3 2017: $5.14 million | Q1 2018: $4.58 million | Q2 2018: $4.07 million | Q3 2018: $3.99 million | Q1 2019: $4.08 million | Q2 2019: $3.90 million | Q3 2019: $3.52 million | Q1 2020: $3.37 million | Q2 2020: $4.80 million | Q3 2020: $4.19 million | Q1 2021: $1.94 million | Q2 2021: $1.85 million | Q3 2021: $1.76 million | Q1 2022: $2.00 million | Q2 2022: $2.04 million | Q3 2022: $3.59 million | Q1 2023: $4.08 million | Q2 2023: $2.46 million | Q3 2023: $2.46 million | Q1 2024: $1.91 million.
  • Over the full 13 years of available data (2011 to 2023), Traws Pharma, Inc.'s Research And Development Expense has declined by 49.5%.
  • Historical annual values: Fiscal year 2023: $11.43 million | Fiscal year 2022: $11.41 million | Fiscal year 2021: $7.30 million | Fiscal year 2020: $16.90 million | Fiscal year 2019: $15.54 million | Fiscal year 2018: $16.92 million | Fiscal year 2017: $19.12 million | Fiscal year 2016: $20.07 million | Fiscal year 2015: $25.90 million | Fiscal year 2014: $49.43 million | Fiscal year 2013: $50.18 million | Fiscal year 2012: $52.76 million | Fiscal year 2011: $22.62 million.
  • Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: